ClinicalTrials.gg
CompletedNCT02670538Updated Mar 12, 2019Results posted

Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder

A Phase 3 interventional study of Cariprazine and Placebo in Bipolar Disorder and Depression, sponsored by Forest Laboratories. Completed at 89 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-03-12.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
493
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Bipolar Disorder by AbbVie — 2 open to participants now, 2 under way, none of them phase 3. Bipolar Disorder · AbbVie.

Enrollment
2nd of 11
493 · median 234
Started
2016
with 1 other
Phase 3
3 of 11
none open now
Registered
6th of 11
by date

Among the 11 studies in Bipolar Disorder by AbbVie, this one is the 2nd largest by enrollment, is one of 2 that started in 2016, is one of 3 in phase 3, and was the 6th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 11 studies in Bipolar Disorder by AbbVie are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Bipolar Disorder by AbbVie, or all of them as a file.
02

Study summary

This study is designed to prospectively confirm the efficacy of a fixed-dose regimen of cariprazine 1.5 milligrams (mg)/day or 3 mg/day compared to placebo for treatment of the depressive episode in participants with bipolar I disorder. The safety and tolerability of the fixed-dose regimens will be evaluated.

03

Conditions studied

  • Bipolar Disorder
  • Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently meet the , Fifth Edition (DSM-5) criteria for bipolar I disorder without psychotic features confirmed by the administration of the Mini International Neuropsychiatric Interview (MINI), with a current major depressive episode of at least 4 weeks and not exceeding 12 months in duration
  • Currently treated as an outpatient at the time of enrollment
  • A verified previous manic or mixed episode. Verification must include one of the following sources:

    • Treatment of mania with an anti-manic agent (eg, lithium or divalproate) or antipsychotic medication with an approved indication for mania
    • Hospital records/Medical records
    • Patient report corroborated by caretaker or previous or current treating clinician
  • 17-item Hamilton Depression Rating Scale (HAMD-17) total score ≥ 20
  • HAMD-17 item 1 score ≥ 2
  • CGI-S score ≥ 4
  • Negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test (women of only)
  • Normal physical examination, clinical laboratory test results, and (ECG) results or abnormal findings that are judged not by the Principal Investigator (PI)

Exclusion criteria

Exclusion Criteria:

  • Young Mania Rating Scale (YMRS) total score > 12
  • Four or more episodes of a mood disturbance (depression, mania, hypomania, or mixed state) within the 12 months before Visit 1
  • Any current axis 1 psychiatric diagnosis other than bipolar disorder with the exception of specific phobias
  • History of meeting criteria for:

    • Dementia, amnesic, or other cognitive disorder
    • Schizophrenia, schizoaffective, or other psychotic disorder
    • Mental retardation
  • DSM-5-based diagnosis of borderline or antisocial personality disorder or other axis II disorder of sufficient severity to interfere with participation in this study
  • History of meeting DSM-5 criteria for alcohol or substance abuse or dependence (other than nicotine or caffeine) within the 6 months before Visit 1
  • Positive result on blood alcohol test or urine drug screen for any prohibited medication. Exception:

    • Patients with a positive cannabinoid on entry may be retested before randomization. If the patient remains positive, the patient is no longer eligible
    • Patients positive for opiates on entry, discussion with Study Physician is required.
  • Electroconvulsive therapy in the 3 months before Visit 1
  • Previous lack of response to electroconvulsive therapy
  • Treatment with a depot antipsychotic drug within 1 treatment cycle before Visit 1
  • Treatment with clozapine in a dose of > 50 mg/day in the past 2 years
  • Prior participation in any study of RGH-188 or cariprazine within the past 12 months
  • Previous treatment with vagus nerve stimulation or transcranial magnetic stimulation within 6 months before Visit 1
  • Prior participation with any clinical trials, involving experimental or investigational drugs, within 6 months before Visit 1 or during the study
  • Initiation or termination of psychotherapy for depression within the 3 months preceding Visit 1, or plans to initiate, terminate, or change such therapy during the course of the study.
  • Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
  • Gastric bypass or any condition that would be expected to affect drug absorption (lap band procedures are acceptable if there is no problem with absorption)
  • Known history of cataracts or retinal detachment
  • Known infection
  • Employee, or immediate relative of an employee, of the Sponsor, any of its affiliates or partners, or the study center
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
493 participants (actual)

Study arms

  • Experimental
    Cariprazine 3.0 mg

    Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligrams (mg) capsule, one per day, orally for 2 weeks increased to cariprazine 3.0 mg capsule, one per day orally beginning on Day 15 for 4 weeks.

    Drug: Cariprazine

  • Experimental
    Cariprazine 1.5 mg

    Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day, orally for 6 weeks.

    Drug: Cariprazine

  • Placebo comparator
    Placebo

    Following a 7 to 14 days screening/washout period, matching placebo capsule, one per day, orally for 6 weeks.

    Drug: Placebo

Interventions

  • Cariprazine capsule one per day orally.

    Also known as: Vraylar

  • DrugPlacebo

    Matching placebo capsule one per day orally.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)

    MADRS is a 10-item, clinician-rated scale that evaluates the participants depressive symptomatology during the past week. Participants were rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each of the 10 items was scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity for a total possible score of 0 (best) to 60 (worst). A negative change from Baseline indicates improvement. Mixed-effects Model for Repeated Measures (MMRM) with fixed factors (treatment group, pooled study center, and visit), baseline (a covariate), and interactions (treatment group by visit, baseline by visit).

    Time frame: Baseline (Week 0) to Week 6

Secondary outcomes

  1. Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score

    CGI-S is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of other patients the physician has observed. The participant was rated on a scale from 1 to 7, with 1 indicating a "normal state" and 7 indicating "among the most extremely ill patients". A negative change from Baseline indicates improvement. MMRM with fixed factors (treatment group, pooled study center, and visit), baseline (a covariate), and interactions (treatment group by visit, baseline by visit).

    Time frame: Baseline (Week 0) to Week 6

07

Results

Posted Feb 5, 2019

Participant flow

Participant flow — Overall Study
MilestonePlaceboCariprazine 1.5 mgCariprazine 3.0 mg
Started167168158
Safety population : received study drug165167158
Intent-to-treat population163162153
Completed135136128
Not completed323230
Withdrew: Withdrawal of consent865
Withdrew: Lost to follow-up8127
Withdrew: Adverse event5511
Withdrew: Lack of efficacy712
Withdrew: Protocol violation341
Withdrew: Noncompliance with study drug132
Withdrew: Other miscellaneous reasons012

Outcome measures

PrimaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)

MADRS is a 10-item, clinician-rated scale that evaluates the participants depressive symptomatology during the past week. Participants were rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each of the 10 items was scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity for a total possible score of 0 (best) to 60 (worst). A negative change from Baseline indicates improvement. Mixed-effects Model for Repeated Measures (MMRM) with fixed factors (treatment group, pooled study center, and visit), baseline (a covariate), and interactions (treatment group by visit, baseline by visit).

Time frame:
Baseline (Week 0) to Week 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)
score on a scalePlaceboCariprazine 1.5 mgCariprazine 3.0 mg
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)-12.4 ± 0.75-14.8 ± 0.76-14.1 ± 0.78
Statistical analysis
  • Placebo vs Cariprazine 1.5 mg · Contrast t-test · p = 0.0417 (Adjusted p-value: adjustment was performed using matched parallel gatekeeping procedure to control the overall type I error rate for multiple comparisons of 2 active doses versus placebo at Week 6.) · Least squares (ls) mean difference: -2.5 · 95% CI -4.6 to -0.4
  • Placebo vs Cariprazine 3.0 mg · Contrast t-test · p = 0.1051 (Adjusted p-value: adjustment was performed using matched parallel gatekeeping procedure to control the overall type I error rate for multiple comparisons of 2 active doses versus placebo at Week 6.) · Ls mean difference: -1.8 · 95% CI -3.9 to 0.4
SecondaryChange From Baseline in Clinical Global Impressions-Severity (CGI-S) Score

CGI-S is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of other patients the physician has observed. The participant was rated on a scale from 1 to 7, with 1 indicating a "normal state" and 7 indicating "among the most extremely ill patients". A negative change from Baseline indicates improvement. MMRM with fixed factors (treatment group, pooled study center, and visit), baseline (a covariate), and interactions (treatment group by visit, baseline by visit).

Time frame:
Baseline (Week 0) to Week 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score
score on a scalePlaceboCariprazine 1.5 mgCariprazine 3.0 mg
Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score-1.2 ± 0.09-1.5 ± 0.09-1.4 ± 0.09
Statistical analysis
  • Placebo vs Cariprazine 1.5 mg · Contrast t-test · p = 0.0417 (Adjusted p-value: adjustment was performed using matched parallel gatekeeping procedure to control the overall type I error rate for multiple comparisons of 2 active doses versus placebo at Week 6.) · Ls mean difference: -0.3 · 95% CI -0.6 to -0.1
  • Placebo vs Cariprazine 3.0 mg · Contrast t-test · p = 0.1370 (Adjusted p-value: adjustment was performed using matched parallel gatekeeping procedure to control the overall type I error rate for multiple comparisons of 2 active doses versus placebo at Week 6.) · Ls mean difference: -0.2 · 95% CI -0.4 to 0.1

Adverse events

Collected over First dose of study drug up to Day 50. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/165 (0%)5/165 (3%)36/165 (21.8%)
Cariprazine 1.5 mg0/167 (0%)1/167 (0.6%)45/167 (26.9%)
Cariprazine 3.0 mg0/158 (0%)1/158 (0.6%)45/158 (28.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboCariprazine 1.5 mgCariprazine 3.0 mg
AbortionPregnancy, puerperium and perinatal conditions0/970/1071/103
Non-cardiac chest painGeneral disorders1/1650/1670/158
Lumbar vertebral fractureInjury, poisoning and procedural complications1/1650/1670/158
Bipolar disorderPsychiatric disorders1/1650/1670/158
ManiaPsychiatric disorders1/1650/1670/158
Substance abusePsychiatric disorders1/1650/1670/158
DepressionPsychiatric disorders0/1651/1670/158
Most frequent other events
Most frequent other events
EventPlaceboCariprazine 1.5 mgCariprazine 3.0 mg
AkathisiaNervous system disorders3/1659/16715/158
HeadacheNervous system disorders14/16514/16714/158
NauseaGastrointestinal disorders5/16513/1678/158
InsomniaPsychiatric disorders7/1658/16711/158
RestlessnessPsychiatric disorders5/1654/16711/158
AgitationPsychiatric disorders10/1653/1677/158
FatigueGeneral disorders2/1659/1675/158

Baseline characteristics

Randomized Population consisted of all participants in the Screened Population who were randomized to a treatment group in the study.

Age, Continuous
Age, Continuous(years)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgTotal
Mean44.4 ± 11.642.2 ± 12.043.9 ± 11.843.5 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgTotal
Female99107103309
Male686155184
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgTotal
White121121117359
Black or African American464139126
Asian0325
Multiple Races0303
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgTotal
Hispanic or Latino18221555
Not Hispanic or Latino149146143438
Montgomery-Åsberg Depression Rating Scale (MADRS)
Montgomery-Åsberg Depression Rating Scale (MADRS)(score on a scale)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgTotal
Mean31.4 ± 4.531.5 ± 4.331.5 ± 4.831.5 ± 4.5
08

Study locations

89 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Harmonex Neuroscience Research, Inc.
    Dothan, Alabama 36303, United States
  • NoesisPharma, LLC
    Phoenix, Arizona 85032, United States
  • Woodland International Research Group, LLC
    Little Rock, Arkansas 72211, United States
  • Advanced Research Center, Inc
    Anaheim, California 92805, United States
  • Radiant Research
    Cerritos, California 90703, United States
  • Collaborative Neuroscience Network, LLC
    Garden Grove, California 92845, United States
  • Behavioral Research Specialists, LLC
    Glendale, California 91206, United States
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • Collaborative Neuroscience Network, LLC
    Torrance, California 90502, United States
  • Comprehensive Clinical Research
    Washington, District of Columbia 20016, United States
  • CNS Clinical Research Group
    Coral Springs, Florida 33067, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Innovative Clinical Research, Inc.
    Lauderhill, Florida 33319, United States
  • Innova Clinical Trials, Inc.
    Miami, Florida 33133, United States
  • Research Centers of America, LLC
    Oakland Park, Florida 33334, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Alexian Brothers Center for Psychiatric Research
    Hoffman Estates, Illinois 60169, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • Baber Research Group
    Naperville, Illinois 60563, United States
  • J. Gary Booker, MD, APMC
    Shreveport, Louisiana 71104, United States
  • Coastal Research Associates, Inc.
    Weymouth, Massachusetts 02190, United States
  • Millennium Psychiatric Associates
    Creve Coeur, Missouri 63141, United States
  • St. Louis Clinical Trials, LLC
    Saint Louis, Missouri 63141, United States
  • Center for Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • Pharmaceutical Research Associates, Inc.
    Marlton, New Jersey 08053, United States
  • Brooklyn Medical Institute
    Brooklyn, New York 11214, United States
  • SPRI Clinical Trials, LLC
    Brooklyn, New York 11235, United States
  • University at Buffalo Erie County Medical Center
    Buffalo, New York 14215, United States
  • Manhattan Behavioral Medicine
    New York, New York 10036, United States
  • Eastside Comprehensive Medical Center
    New York, New York 10128, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Clinical Trials of America, Inc
    Hickory, North Carolina 28601, United States
  • University of Cincinnati - Department of Psychiatry and Behavioral Neuroscience
    Cincinnati, Ohio 45219, United States
  • Professional Psychiatric Services
    Mason, Ohio 45040, United States
  • Cutting Edge Research Group
    Oklahoma City, Oklahoma 73116, United States
  • Tulsa Clinical Research, LLC
    Tulsa, Oklahoma 74104, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Carolina Clinical Trials, Inc.
    Charleston, South Carolina 29407, United States
  • Houston Endoscopy and Research Center
    Houston, Texas 77079, United States
  • Grayline Research Center
    Wichita Falls, Texas 76309, United States
  • Pacific Institute of Medical Sciences
    Bothell, Washington 98011, United States
  • Mental Health Centre 'Prof. Dr. Ivan Temkov', EOOD
    Burgas, 8001, Bulgaria
  • MHAT "Dr. Hristo Stambolski", EOOD
    Kazanlak, 6100, Bulgaria
  • UMHAT 'Dr. Georgi Stranski', Dept. of Psychiatry
    Pleven, 5800, Bulgaria
  • UMHAT "Sv. Georgi", EAD
    Plovdiv, 4000, Bulgaria
  • DCC "Mladost M" - Varna, OOD Site 188
    Varna, 9020, Bulgaria
  • DCC "Mladost M" - Varna, OOD Site 194
    Varna, 9020, Bulgaria
  • Neuropsychiatric Hospital Ivan Barbot
    Popovača, 44317, Croatia
  • Clinical Hospital Center Rijeka
    Rijeka, 51000, Croatia
  • Polyclinic Neuron
    Zagreb, 10000, Croatia
  • University Hospital Center Zagreb
    Zagreb, 10000, Croatia
  • Clinic for Psychiatry Vrapce
    Zagreb, 10090, Croatia
  • Psychiatric Hospital "Sveti Ivan"
    Zagreb, 10090, Croatia
  • Barbara Diaz-Hernandez MD Research, Inc.
    San Juan, 00926, Puerto Rico
  • Spitalul Universitar de Urgenta Militar Central "Dr. Carol Davila"
    Bucuresti, 010825, Romania
  • Spitalul de Psihiatrie Titan "Dr. Constantin Gorgos"
    Bucuresti, 030442, Romania
  • Spitalul de Psihiatrie "Elisabeta Doamna" Galati
    Galati, 800179, Romania
  • Institutul de Psihiatrie Socola Iasi Site 111
    Iasi, 700282, Romania
  • Institutul de Psihiatrie Socola Iasi Site 113
    Iasi, 700282, Romania
  • Clinic of Psychiatric Diseases "Dr Laza Lazarevic"
    Belgrade, 11000, Serbia
  • Clinical Center of Serbia
    Belgrade, 11000, Serbia
  • Clinical Center Zvezdara
    Belgrade, 11000, Serbia
  • General Hospital Euromedic
    Belgrade, 11000, Serbia
  • Institute of Mental Health
    Belgrade, 11000, Serbia
  • Clinical Center "Dr. Dragisa Misovic"
    Belgrade, 11040, Serbia
  • Clinical Center Kragujevac Site 154
    Kragujevac, 34000, Serbia
  • Clinical Centre Kragujevac Site 158
    Kragujevac, 34000, Serbia
  • Clinical Center Nis Site 150
    Nis, 18000, Serbia
  • Clinical Center Nis Site 160
    Nis, 18000, Serbia
  • Specialized Hospital for Neuropsychiatric Diseases "Sveti Vracevi"
    Novi Knezevac, 23330, Serbia
  • Centrum zdravia R.B.K. s.r.o.
    Bardejov, 08501, Slovakia
  • Vavrusova Consulting s.r.o.
    Bratislava, 85101, Slovakia
  • Liptovska nemocnica s poliklinikou Liptovsky Mikulas
    Liptovsky Mikulas, 03123, Slovakia
  • PsychoLine s.r.o.
    Rimavská Sobota, 97901, Slovakia
  • Nemocnica s poliklinikou sv. Barbory, Roznava a.s.
    Rožňava, 04801, Slovakia
  • Crystal Comfort s.r.o.
    Vranov nad Toplou, 09301, Slovakia
  • CI of Kyiv Reg.Council Reg.Psychiatric-Narcological Medical Association
    Glevakha, 08631, Ukraine
  • Regional Psychoneurological Hospital #3, Dept of Primary Psych Episode
    Ivano-Frankivsk, 76014, Ukraine
  • Regional Psychoneurological Hospital #3
    Ivano-Frankivsk, 76014, Ukraine
  • SI Inst.of Neurology, Psychiatry and Narcology of NAMS of Ukraine
    Kharkiv, 61068, Ukraine
  • CI Kherson Reg. Psychiatric Hospital of Kherson RC
    Kherson, 73488, Ukraine
  • CI Odesa Regional Psychiatric Hospital # 2
    Komintern, 67513, Ukraine
  • CI of LRC Lviv Reg. Council Lviv Reg.Clinical Psychoneurological Dispensary
    Lviv, 79017, Ukraine
  • CI Odesa Regional Medical Center of Mental Health
    Odesa, 65006, Ukraine
  • CI Cherkasy Regional Psychiatric Hospital of ChRC
    Smila, 20708, Ukraine
  • Ternopil Reg. Communal Clinical Psychoneurological Hospital Depts of Psychiatry #2
    Ternopil, 46027, Ukraine
  • Transcarpathian Regional Narcological Dispensary
    Uzhgorod, 88000, Ukraine
  • CI O.I. Yushchenko Vinnytsia Reg. Psychoneurological Hospital
    Vinnytsia, 21005, Ukraine
09

References and documents

Publications

  • Citrome L, Yatham LN, Patel MD, Barabassy A, Hankinson A, Earley WR. Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression. J Affect Disord. 2021 Jun 1;288:191-198. doi: 10.1016/j.jad.2021.03.076. Epub 2021 Mar 31. PubMed 33915374 ↗
  • Thase ME, Harrington A, Calabrese J, Montgomery S, Niu X, Patel MD. Evaluation of MADRS severity thresholds in patients with bipolar depression. J Affect Disord. 2021 May 1;286:58-63. doi: 10.1016/j.jad.2021.02.043. Epub 2021 Feb 20. PubMed 33677183 ↗
  • Yatham LN, Vieta E, McIntyre RS, Jain R, Patel M, Earley W. Broad Efficacy of Cariprazine on Depressive Symptoms in Bipolar Disorder and the Clinical Implications. Prim Care Companion CNS Disord. 2020 Sep 17;22(5):20m02611. doi: 10.4088/PCC.20m02611. PubMed 32942346 ↗
  • Earley WR, Burgess M, Rekeda L, Hankinson A, McIntyre RS, Suppes T, Calabrese JR, Yatham LN. A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression. J Affect Disord. 2020 Feb 15;263:386-395. doi: 10.1016/j.jad.2019.11.098. Epub 2019 Nov 22. PubMed 31969269 ↗
  • Earley WR, Burgess MV, Khan B, Rekeda L, Suppes T, Tohen M, Calabrese JR. Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study. Bipolar Disord. 2020 Jun;22(4):372-384. doi: 10.1111/bdi.12852. Epub 2019 Nov 6. PubMed 31628698 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Jan 2018, 21 months.

Results were first posted in Feb 2019, 1 year after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 21 months is below that.

Counting every sponsor, half of 43 studies reached it within 37 months; a quarter within 21 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2016
First posted
Feb 1, 2016
StartActual
Mar 31, 2016
Primary completionActual
Jan 18, 2018
CompletionActual
Jan 18, 2018
Results first posted
Feb 5, 2019
Last update
Mar 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02670538
Responsible party
Sponsor
First posted
Feb 1, 2016
Start date
Mar 31, 2016
Primary completion
Jan 18, 2018
Completion
Jan 18, 2018
Results posted
Feb 5, 2019
Last update
Mar 12, 2019

Study contacts

Willie Earley
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion